JP2014526503A5 - - Google Patents

Download PDF

Info

Publication number
JP2014526503A5
JP2014526503A5 JP2014530636A JP2014530636A JP2014526503A5 JP 2014526503 A5 JP2014526503 A5 JP 2014526503A5 JP 2014530636 A JP2014530636 A JP 2014530636A JP 2014530636 A JP2014530636 A JP 2014530636A JP 2014526503 A5 JP2014526503 A5 JP 2014526503A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
compound
bendamustine
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014530636A
Other languages
English (en)
Japanese (ja)
Other versions
JP6330118B2 (ja
JP2014526503A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/051470 external-priority patent/WO2013039488A1/en
Publication of JP2014526503A publication Critical patent/JP2014526503A/ja
Publication of JP2014526503A5 publication Critical patent/JP2014526503A5/ja
Application granted granted Critical
Publication of JP6330118B2 publication Critical patent/JP6330118B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014530636A 2011-09-13 2011-09-13 ベンダムスチンと組み合わせたヒストンデアセチラーゼ阻害剤の製剤とその使用 Active JP6330118B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/051470 WO2013039488A1 (en) 2011-09-13 2011-09-13 Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof

Publications (3)

Publication Number Publication Date
JP2014526503A JP2014526503A (ja) 2014-10-06
JP2014526503A5 true JP2014526503A5 (US20040106767A1-20040603-C00005.png) 2014-11-20
JP6330118B2 JP6330118B2 (ja) 2018-05-30

Family

ID=47883567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014530636A Active JP6330118B2 (ja) 2011-09-13 2011-09-13 ベンダムスチンと組み合わせたヒストンデアセチラーゼ阻害剤の製剤とその使用

Country Status (15)

Country Link
US (1) US9492423B2 (US20040106767A1-20040603-C00005.png)
EP (1) EP2755648B1 (US20040106767A1-20040603-C00005.png)
JP (1) JP6330118B2 (US20040106767A1-20040603-C00005.png)
KR (1) KR101892788B1 (US20040106767A1-20040603-C00005.png)
CN (1) CN103917231B (US20040106767A1-20040603-C00005.png)
AU (1) AU2011376953B2 (US20040106767A1-20040603-C00005.png)
CA (1) CA2845806C (US20040106767A1-20040603-C00005.png)
ES (1) ES2627820T3 (US20040106767A1-20040603-C00005.png)
HK (1) HK1200095A1 (US20040106767A1-20040603-C00005.png)
MX (1) MX365393B (US20040106767A1-20040603-C00005.png)
NZ (1) NZ621221A (US20040106767A1-20040603-C00005.png)
RU (1) RU2609833C2 (US20040106767A1-20040603-C00005.png)
SG (1) SG2014014419A (US20040106767A1-20040603-C00005.png)
UA (1) UA110853C2 (US20040106767A1-20040603-C00005.png)
WO (1) WO2013039488A1 (US20040106767A1-20040603-C00005.png)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2529147T3 (es) 2006-12-26 2015-02-17 Pharmacyclics, Inc. Método para usar los inhibidores de la histona deacetilasa y monitorear biomarcadores en la terapia de combinación
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
EP3226903A1 (en) * 2014-12-05 2017-10-11 University of Modena and Reggio Emila Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma
US20180185345A1 (en) * 2015-06-19 2018-07-05 Trustees Of Boston University Methods and compositions for treating herpesvirus induced conditions
PL3439649T3 (pl) 2016-04-08 2024-03-18 Cereno Scientific Ab Preparaty farmaceutyczne o opóźnionym uwalnianiu zawierające kwas walproinowy i ich zastosowanie
US20200179381A1 (en) * 2016-04-08 2020-06-11 Cereno Scientific Ab Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
KR20220100077A (ko) * 2016-04-21 2022-07-14 발큐리아 에이비 암의 예비치료용 조성물 및 방법
AU2016426574B2 (en) 2016-10-11 2023-07-13 Euro-Celtique S.A. Hodgkin lymphoma therapy
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
SG10201609137PA (en) * 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Gamma-polyglutamic acid and zinc compositions
GB201706544D0 (en) * 2017-04-25 2017-06-07 Plasticell Ltd Method
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
KR102338992B1 (ko) * 2018-01-05 2021-12-14 지엔티 바이오테크 & 메디컬즈 코포레이션 종양 미세환경 및 면역요법의 조절을 위한 약제학적 조합물 및 방법
EP3976198A4 (en) 2019-05-31 2023-07-19 Viracta Subsidiary, Inc. METHODS OF TREATMENT OF VIRAL ASSOCIATED CANCER WITH HISTONE DEACETYLASE INHIBITORS
WO2022159852A1 (en) * 2021-01-25 2022-07-28 Icahn School Of Medicine At Mount Sinai Methods and compositions for treating adenoid cystic carcinoma
WO2024086688A1 (en) * 2022-10-21 2024-04-25 Viracta Subsidiary, Inc. Dosing methods for hdac inhibitor compounds

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) 1964-03-24 Chioacyl
US2789118A (en) 1956-03-30 1957-04-16 American Cyanamid Co 16-alpha oxy-belta1, 4-pregnadienes
US2990401A (en) 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3048581A (en) 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3749712A (en) 1970-09-25 1973-07-31 Sigma Tau Ind Farmaceuti Triamcinolone acetonide esters and process for their preparation
BE794063A (fr) 1972-01-17 1973-07-16 Henkel & Cie Gmbh Anti-inflammatoires pour compositions cosmetiques
US3996359A (en) 1972-05-19 1976-12-07 Ab Bofors Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
SE378110B (US20040106767A1-20040603-C00005.png) 1972-05-19 1975-08-18 Bofors Ab
SE378109B (US20040106767A1-20040603-C00005.png) 1972-05-19 1975-08-18 Bofors Ab
US3775656A (en) 1972-05-22 1973-11-27 Aviat Inc Platform stabilization system
CH581818A5 (US20040106767A1-20040603-C00005.png) 1973-02-27 1976-11-15 Cierva Juan J De
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
EP0084236A3 (en) 1981-12-22 1983-08-03 Fbc Limited Fungicidal heterocyclic compounds and compositions containing them
US4498038A (en) 1983-02-15 1985-02-05 Malueg Richard M Stabilization system for soft-mounted platform
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
EP0230654B1 (en) 1985-12-28 1992-03-18 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
DE3889545T2 (de) 1987-10-20 1994-10-13 Otsuka Pharma Co Ltd Phenylcarbonsäure-abkömmlinge.
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
JPH03215470A (ja) 1990-01-22 1991-09-20 Suntory Ltd プロピオン酸アミド誘導体,その製造法及びそれを有効成分として含有する除草剤
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
DE4124345A1 (de) 1991-07-23 1993-01-28 Gruenenthal Gmbh Substituierte 3,4-dihydronaphthaline, diese verbindungen enthaltende arzneimittel und verfahren zur herstellung dieser verbindungen und arzneimittel
CA2122479C (en) 1991-11-22 1998-08-25 Richard John Dansereau Risedronate delayed-release compositions
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5700410A (en) 1992-10-16 1997-12-23 Nippon Shinyaku Co., Ltd. Method of manufacturing wax matrices
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE4327365A1 (de) 1993-08-14 1995-02-16 Boehringer Mannheim Gmbh Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung
US5448938A (en) 1993-10-18 1995-09-12 Guardian Technologies International, Inc. Removable ballistic resistant armor seat cover and floor mat
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5958957A (en) 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6211197B1 (en) 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1191861A4 (en) 1999-05-28 2006-12-06 David E Grober AUTONOMOUS, SELF-LEVELING AND SELF-CORRECTIVE STABILIZING PLATFORM
US6718130B2 (en) 1999-05-28 2004-04-06 David E. Grober Stabilized camera and marker buoy for media coverage of aquatic events
JP2003506100A (ja) 1999-08-10 2003-02-18 パンジーン・コーポレイション Rad51関連分子および方法を用いる癌治療および診断
AU6936500A (en) 1999-08-24 2001-03-19 Regents Of The University Of California, The Non-quinoline inhibitors of malaria parasites
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
ATE247657T1 (de) 1999-09-17 2003-09-15 Basf Ag Pyrazolopyrimidine als arzneimittel
CA2391952C (en) 1999-11-23 2012-01-31 Methylgene Inc. Inhibitors of histone deacetylase
WO2002017918A2 (en) 2000-08-30 2002-03-07 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
JP4975941B2 (ja) 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド (e)−n−ヒドロキシ−3−(3−スルファモイル−フェニル)アクリルアミド化合物及びその治療用途
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
DE60129043T2 (de) 2000-12-28 2008-02-21 Epidauros Biotechnologie Ag Identifizierung von genetischen determinanten der polymorphen cyp3a5 expression
MXPA01013172A (es) 2001-02-14 2002-08-21 Warner Lambert Co Inhibidores sulfonamida de metaloproteinasa de matriz.
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
PT1404304E (pt) 2001-06-28 2009-06-26 Ucb Farchim Sa Comprimido contendo cetirizina e pseudoefedrina
US7247426B2 (en) 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
ITMI20011733A1 (it) 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
ES2371630T3 (es) 2001-08-21 2012-01-05 Astellas Pharma Inc. Uso medicinal de un inhibidor de histona desacetilasa y método para evaluar su efecto antitumoral.
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20030166026A1 (en) 2002-01-09 2003-09-04 Lynx Therapeutics, Inc. Identification of specific biomarkers for breast cancer cells
JP2005516626A (ja) 2002-02-04 2005-06-09 エピダウロス バイオテクノロジー アーゲー Tpmtのヒト遺伝子における多型ならびに診断的適用および治療的適用におけるその使用方法
JPWO2003070691A1 (ja) 2002-02-21 2005-06-09 財団法人大阪産業振興機構 N−ヒドロキシカルボキサミド誘導体
US20040132825A1 (en) 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
KR20050034732A (ko) 2002-08-02 2005-04-14 아젠터 디스커버리 리미티드 히스톤 디아세틸라제 억제제로서의 치환된티에닐-히드록사믹산
EP1400806A1 (en) 2002-09-18 2004-03-24 G2M Cancer Drugs AG The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity
US6769347B1 (en) 2002-11-26 2004-08-03 Recon/Optical, Inc. Dual elevation weapon station and method of use
CA2519320A1 (en) 2003-02-19 2004-09-02 Astellas Pharma Inc. Method of estimating antitumor effect of histone deacetylase inhibitor
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
BRPI0409227C1 (pt) 2003-04-07 2021-05-25 Axys Pharm Inc composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
ZA200507751B (en) * 2003-04-07 2007-01-31 Axys Pharm Inc Novel hydroxamates as therapeutic agents
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
JP4779971B2 (ja) 2003-09-25 2011-09-28 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤とトポイソメラーゼii阻害剤とからなる抗腫瘍剤
WO2005043161A2 (en) 2003-11-04 2005-05-12 Roche Diagnostics Gmbh Method for distinguishing leukemia subtypes
CA2549324A1 (en) 2003-12-12 2005-06-30 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
WO2005086891A2 (en) 2004-03-05 2005-09-22 Rosetta Inpharmatics Llc Classification of breast cancer patients using a combination of clinical criteria and informative genesets
GB2427405A (en) 2004-04-07 2006-12-27 Pharmacyclics Inc Novel hydroxamates as therapeutic agents
PL1591109T3 (pl) 2004-04-30 2008-11-28 Topotarget Germany Ag Preparat zawierający inhibitor deacetylazy histonów wykazujący dwufazowe uwalnianie”
BRPI0511065A (pt) 2004-06-04 2007-12-26 Pfizer Prod Inc método para tratar crescimento de célula anormal
US20090239214A1 (en) 2004-07-30 2009-09-24 Hongyue Dai Prognosis of breast cancer patients
WO2006042035A2 (en) 2004-10-07 2006-04-20 Pharmacyclics, Inc. Method of monitoring anti-tumor activity of an hdac inhibitor
JP2008519047A (ja) * 2004-11-05 2008-06-05 セフアロン・インコーポレーテツド 癌処置
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
WO2006101454A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Benzothiophene derivatives: preparation and pharmaceutical applications
WO2007109178A2 (en) 2006-03-16 2007-09-27 Pharmacyclics, Inc. Indole derivatives as inhibitors of histone deacetylase
CA2659070C (en) 2006-09-15 2014-10-21 Janssen Pharmaceutica Nv Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors
ES2529147T3 (es) * 2006-12-26 2015-02-17 Pharmacyclics, Inc. Método para usar los inhibidores de la histona deacetilasa y monitorear biomarcadores en la terapia de combinación
WO2008095050A1 (en) 2007-01-30 2008-08-07 Pharmacyclics, Inc. Methods for determining cancer resistance to histone deacetylase inhibitors
EP2060565A1 (en) * 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
EP2110377A1 (en) * 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
UY34295A (es) 2011-09-08 2013-04-30 Servier Lab Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
US9421208B2 (en) 2013-08-02 2016-08-23 Pharmacyclics Llc Methods for the treatment of solid tumors

Similar Documents

Publication Publication Date Title
JP2014526503A5 (US20040106767A1-20040603-C00005.png)
RU2014111069A (ru) Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
JP2019503365A5 (US20040106767A1-20040603-C00005.png)
JP2012255026A5 (US20040106767A1-20040603-C00005.png)
JP2018109022A5 (US20040106767A1-20040603-C00005.png)
JP2017057230A5 (US20040106767A1-20040603-C00005.png)
JP2006514689A5 (ja) 1−オキソ−2−(2,6−ジオキソピペリジン−3−イル)−4−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物
JP2016540738A5 (US20040106767A1-20040603-C00005.png)
JP2016515628A5 (US20040106767A1-20040603-C00005.png)
JP2012193216A5 (US20040106767A1-20040603-C00005.png)
JP2015512406A5 (US20040106767A1-20040603-C00005.png)
JP2014515373A5 (US20040106767A1-20040603-C00005.png)
JP2015522630A5 (US20040106767A1-20040603-C00005.png)
JP2006504795A5 (US20040106767A1-20040603-C00005.png)
JP2011529968A5 (US20040106767A1-20040603-C00005.png)
JP2015038135A5 (US20040106767A1-20040603-C00005.png)
JP2015536964A5 (US20040106767A1-20040603-C00005.png)
JP2012525393A5 (US20040106767A1-20040603-C00005.png)
JP2011173928A5 (US20040106767A1-20040603-C00005.png)
JP2013507415A5 (US20040106767A1-20040603-C00005.png)
JP2009514874A5 (US20040106767A1-20040603-C00005.png)
JP2017537126A5 (US20040106767A1-20040603-C00005.png)
JP2013522326A5 (US20040106767A1-20040603-C00005.png)
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2012533565A5 (US20040106767A1-20040603-C00005.png)